Myeloablative therapy with autologous stem cell rescue for patients with Ewing sarcoma

The aim of this study was to identify risk factors associated with PFS in patients with Ewing sarcoma undergoing ASCT; 116 patients underwent ASCT in 1989–2000 and reported to the Center for International Blood and Marrow Transplant Research. Eighty patients (69%) received ASCT as first-line therapy...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2008-05, Vol.41 (10), p.867-872
Hauptverfasser:	Gardner, S L, Carreras, J, Boudreau, C, Camitta, B M, Adams, R H, Chen, A R, Davies, S M, Edwards, J R, Grovas, A C, Hale, G A, Lazarus, H M, Arora, M, Stiff, P J, Eapen, M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Autografts Biological and medical sciences Bone marrow Bone marrow, stem cells transplantation. Graft versus host reaction Care and treatment Cell Biology Chemotherapy Child Clinical trials Combined Modality Therapy Diagnosis Disease Progression Diseases of the osteoarticular system Ewing's sarcoma Ewings sarcoma Female Health risks Hematology Humans Internal Medicine Irradiation Male Medical sciences Medicine Medicine & Public Health Metastases Metastasis Middle Aged Myeloablative Agonists - therapeutic use original-article Patient outcomes Patients Public Health Risk analysis Risk Factors Risk groups Sarcoma Sarcoma, Ewing - mortality Sarcoma, Ewing - secondary Sarcoma, Ewing - therapy Statistical analysis Stem cell transplantation Stem Cell Transplantation - methods Stem Cells Survival Analysis Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation Transplantation, Autologous Tumors of striated muscle and skeleton
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The aim of this study was to identify risk factors associated with PFS in patients with Ewing sarcoma undergoing ASCT; 116 patients underwent ASCT in 1989–2000 and reported to the Center for International Blood and Marrow Transplant Research. Eighty patients (69%) received ASCT as first-line therapy and 36 (31%), for recurrent disease. Risk factors affecting ASCT were analyzed with use of the Cox regression method. Metastatic disease at diagnosis, recurrence prior to ASCT and performance score
ISSN:	0268-3369 1476-5365
DOI:	10.1038/bmt.2008.2